Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

4.145 +0.095 (+2.35%)
Streaming Delayed Price Updated: 2:37 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
From Bicycle Therapeutics plc
Via Business Wire
News headline image
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics ↗
 
Via Benzinga
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Looking Into Bicycle Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Recap: Bicycle Therapeutics Q3 Earnings ↗
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Bicycle Therapeutics ↗
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Looking Into Bicycle Therapeutics's Return On Capital Employed ↗
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83... 
Via Benzinga
News headline image
Bicycle Therapeutics: Q2 Earnings Insights ↗
  Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗
  
Via Benzinga
News headline image
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Where Bicycle Therapeutics Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.